---
schema_version: "secwatch.filing_event.v1"
accession: "0001701541-24-000028"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:20:11.898113+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Q2 2024 net loss $19.9M; cash runway into Q4 2025; Phase 2 data on track

## Summary
- Cash, equivalents, investments $123.0M at June 30, 2024, down from $131.4M at Dec 31, 2023; runway into Q4 2025.
- Net loss $19.9M in Q2 2024 vs $19.2M in Q2 2023; R&D expenses decreased to $12.6M from $13.2M.
- Initial Phase 2 data for BDTX-1535 in 2L/3L EGFRm NSCLC on track for later Q3 2024; 1L data in Q1 2025.
- Initial Phase 1 data for BDTX-4933 in KRASm NSCLC on track for Q4 2024; ESMO poster in September 2024.

## SEC filing metadata
- accession: 0001701541-24-000028
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000170154124000028/0001701541-24-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000170154124000028/bdtx-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701541-24-000028
- JSON: https://secwatch.observer/filing/0001701541-24-000028.json
- Plain text: https://secwatch.observer/filing/0001701541-24-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.